Jointown H1 2026 Revenue RMB 87.28 Billion, Net Profit RMB 982 Million, B2B Distribution RMB 13.07 Billion

Jointown released its 2026 interim report on the evening of August 24. During the reporting period, the company achieved operating revenue of RMB 87.28 billion, up 7.61% year on year; net profit attributable to shareholders after deducting non-recurring items was RMB 982 million, up 3.22%.

By business segment, pharmaceutical distribution remained stable, with the distribution division generating revenue of RMB 83.20 billion. Among this, B2B digital distribution and supply chain business revenue reached RMB 13.07 billion in the first half, up 22.92% year on year, accounting for 17.69% of overall commercial distribution. The Yao99 B2B e-commerce platform's self-operated sales revenue was RMB 7.50 billion, up 18.89%, with registered users exceeding 678,000 and 330,000 active users. Pharmaceutical supply chain services for leading e-commerce platforms such as JD. com and Alibaba generated revenue of RMB 5.58 billion, up 28.78%. The total agency brand promotion business handled 2,521 product specifications, with medical device total agency revenue of RMB 3.72 billion.

In emerging businesses, pharmaceutical industrial self-produced and OEM operations achieved sales revenue of RMB 1.98 billion, up 24.47%. Jingfeng Pharmaceutical holds over 200 drug approval numbers for formulations and active pharmaceutical ingredients, with 16 drugs passing consistency evaluation. Pharmaceutical new retail revenue was RMB 1.58 billion, and the Haoyaoshi '10,000-store franchise' network reached 36,120 stores, with sales to franchise stores of RMB 4.21 billion (including tax) in the first half, up 23.17%. Digital and intelligent technology service revenue was RMB 54.65 million.

In 2026, the company launched its 'Four New and Two Modernizations' strategy, covering new products, new retail, new healthcare, new services, digitalization, and capitalization. R&D investment in the first half was RMB 161 million, and nine AI agents now cover core business scenarios, with strategic focus shifting from information construction to large-scale deployment of AI agents.

Jointown recently announced a strategic cooperation agreement with National Pension Insurance Co. , Ltd. The two parties will leverage their respective professional advantages through resource integration and innovative collaboration to explore a new 'pharmaceutical services + pension finance' business model. The cooperation is built on the pharmaceutical supply chain, using pharmacy clinics as grassroots touchpoints and medical-nursing entities as service carriers, to advance integrated services for elderly populations covering medication, medical care, nursing, nutrition, and health management.